GleamWall
中文EN

AQST Aquestive Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1398733 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY12.5%
TTM net income YoY-14.9%
TTM EPS YoY7.1%
Revenue 3-yr CAGR0.5%
Net income 3-yr CAGR—

Margins

Gross margin65.3%
Operating margin-114.1%
Net margin-162.3%
FCF margin-83.3%
EBITDA margin-113.0%

Returns

ROE—
ROA-56.0%
ROIC (approx.)—
Asset turnover0.35x

Leverage & solvency

Liabilities / assets159.4%
Debt / equity—
Current ratio6.12x
Interest coverage-5.39x

Cash quality & payout

Operating cash flow / net income0.50x
Accruals ratio-27.9%
Payout ratio—
Capex / revenue1.9%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$44.55M$57.56M
Cost of revenue$18.55M$17.87M
Gross profit$25.99M$39.69M
R&D expense$17.19M$20.28M
SG&A expense$79.85M$50.18M
Operating income-$71.05M-$30.77M
Interest expense$11.12M$11.12M
Pretax income-$83.78M-$44.15M
Income tax$0-$14,000
Net income-$83.78M-$44.14M
EBITDA-$70.50M-$30.05M
EPS (basic)-0.78-0.51
EPS (diluted)-0.78-0.51
Weighted avg. shares (diluted)106.93M86.73M
Balance sheet
Cash & equivalents$121.17M$71.55M
Receivables$17.76M$7.34M
Inventory$6.17M$6.04M
Current assets$149.27M$88.22M
PP&E, net$3.89M$3.80M
Intangibles$0$0
Total assets$160.43M$101.42M
Current liabilities$47.61M$18.86M
Short-term debt$9.99M—
Long-term debt$27.52M$32.50M
Total debt$37.51M$32.50M
Total liabilities$194.09M$161.58M
Shareholders' equity-$33.66M-$60.16M
Net debt-$83.66M-$39.05M
Shares outstanding122.04M91.41M
Cash flow statement
Operating cash flow-$52.43M-$35.76M
Capital expenditure$562,000$159,000
Free cash flow-$52.99M-$35.92M
Investing cash flow-$562,000-$159,000
Financing cash flow$102.62M$83.59M
Depreciation & amortization$548,000$718,000
Stock-based compensation$7.62M$7.10M

Free plan shows the latest 2 periods; Pro shows all 9 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.